China MNPA approves cell therapy GC007g for CD19 positive relapse difficult to treat B-cell acute lymphoblastic leukemia IND
-
Last Update: 2020-06-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Gracell, a clinical-phaseed cell and gene therapy company, recently announced that the National Drug Administration of China (NMPA) has approved the application of GC007g for a new research drug (IND), a donor-derived anti-CD19 embedded antigen receptor CAR-T cell therapyGC007g is an allogeneic CAR-T therapy that is being developed for patients with recurrent refractive B-cell acute lymphoblastic leukemiaThe therapy uses healthy T-cells from human leukocyte antigen (HLA)-matched donors, which are better adaptable and more effective than using the patient's own T-cellsThe company plans to launch a Phase I clinical study of CD19-positive recurrence of refractable B-cell acute lymphoblastic leukemia in the second quarter of 2020Dr William CAO, founder and CEO of Gracell, said: "GC007g's IND marks an important milestone for GracellWe expect donor-derived CAR-T cell therapy to be an alternative for patients who are not suitable for autonomous CAR-T therapy."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
